These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Davis RE; Ngo VN; Lenz G; Tolar P; Young RM; Romesser PB; Kohlhammer H; Lamy L; Zhao H; Yang Y; Xu W; Shaffer AL; Wright G; Xiao W; Powell J; Jiang JK; Thomas CJ; Rosenwald A; Ott G; Muller-Hermelink HK; Gascoyne RD; Connors JM; Johnson NA; Rimsza LM; Campo E; Jaffe ES; Wilson WH; Delabie J; Smeland EB; Fisher RI; Braziel RM; Tubbs RR; Cook JR; Weisenburger DD; Chan WC; Pierce SK; Staudt LM Nature; 2010 Jan; 463(7277):88-92. PubMed ID: 20054396 [TBL] [Abstract][Full Text] [Related]
7. HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization. Boudesco C; Verhoeyen E; Martin L; Chassagne-Clement C; Salmi L; Mhaidly R; Pangault C; Fest T; Ramla S; Jardin F; Wolz OO; Weber ANR; Garrido C; Jego G Blood; 2018 Aug; 132(5):510-520. PubMed ID: 29871863 [TBL] [Abstract][Full Text] [Related]
8. Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825. Wang X; Tan Y; Huang Z; Huang N; Gao M; Zhou F; Hu J; Feng W Oncol Rep; 2019 Nov; 42(5):1755-1766. PubMed ID: 31432184 [TBL] [Abstract][Full Text] [Related]
9. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665 [TBL] [Abstract][Full Text] [Related]
10. The oncogenic human B-cell lymphoma MYD88 L265P mutation genocopies activation by phosphorylation at the Toll/interleukin-1 receptor (TIR) domain. Minderman M; Lantermans H; van der Zwaan C; Hoogendijk AJ; van den Biggelaar M; Kersten MJ; Spaargaren M; Pals ST Blood Cancer J; 2023 Aug; 13(1):125. PubMed ID: 37591861 [TBL] [Abstract][Full Text] [Related]
11. B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice. Knittel G; Liedgens P; Korovkina D; Seeger JM; Al-Baldawi Y; Al-Maarri M; Fritz C; Vlantis K; Bezhanova S; Scheel AH; Wolz OO; Reimann M; Möller P; López C; Schlesner M; Lohneis P; Weber AN; Trümper L; ; Staudt LM; Ortmann M; Pasparakis M; Siebert R; Schmitt CA; Klatt AR; Wunderlich FT; Schäfer SC; Persigehl T; Montesinos-Rongen M; Odenthal M; Büttner R; Frenzel LP; Kashkar H; Reinhardt HC Blood; 2016 Jun; 127(22):2732-41. PubMed ID: 27048211 [TBL] [Abstract][Full Text] [Related]
12. Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling. Turi M; Anilkumar Sithara A; Hofmanová L; Žihala D; Radhakrishnan D; Vdovin A; Knápková S; Ševčíková T; Chyra Z; Jelínek T; Šimíček M; Gullà A; Anderson KC; Hájek R; Hrdinka M Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982699 [TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. Chen Y; Bai G; Ning Y; Cai S; Zhang T; Song P; Zhou J; Duan W; Ding J; Xie H; Zhang H Eur J Med Chem; 2020 Mar; 190():112092. PubMed ID: 32014679 [TBL] [Abstract][Full Text] [Related]
14. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma. Choi JW; Kim Y; Lee JH; Kim YS Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077 [TBL] [Abstract][Full Text] [Related]
15. The Prevalence of MYD88 L265P and TNFAIP3 Mutations and Their Correlations with Clinico-Hematological Profile in Egyptian Patients with Diffuse Large B Cell Lymphoma. Elbaz O; Shaat RM; Abd El Ghaffar HA; Shamaa S; Abdel-Masseih HM; Anber N; Mortada MI Asian Pac J Cancer Prev; 2023 Jul; 24(7):2485-2491. PubMed ID: 37505783 [TBL] [Abstract][Full Text] [Related]
16. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma. Dobashi A J Clin Exp Hematop; 2016; 56(2):71-78. PubMed ID: 27980305 [TBL] [Abstract][Full Text] [Related]
17. Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma. Taniguchi K; Takata K; Chuang SS; Miyata-Takata T; Sato Y; Satou A; Hashimoto Y; Tamura M; Nagakita K; Ohnishi N; Noujima-Harada M; Tabata T; Kikuti YY; Maeda Y; Nakamura N; Tanimoto M; Yoshino T Am J Surg Pathol; 2016 Mar; 40(3):324-34. PubMed ID: 26752547 [TBL] [Abstract][Full Text] [Related]
18. Identification of critical residues of the MyD88 death domain involved in the recruitment of downstream kinases. Loiarro M; Gallo G; Fantò N; De Santis R; Carminati P; Ruggiero V; Sette C J Biol Chem; 2009 Oct; 284(41):28093-28103. PubMed ID: 19679662 [TBL] [Abstract][Full Text] [Related]
19. CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas. Juilland M; Gonzalez M; Erdmann T; Banz Y; Jevnikar Z; Hailfinger S; Tzankov A; Grau M; Lenz G; Novak U; Thome M Blood; 2016 Apr; 127(14):1780-9. PubMed ID: 26747248 [TBL] [Abstract][Full Text] [Related]
20. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis. Lee JH; Jeong H; Choi JW; Oh H; Kim YS Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]